In a significant development for Pakistan’s pharmaceutical industry, Liven Pharma Limited has announced the completion of its first successful export order to the Arab region, marking a major step in the company’s regional expansion strategy.

The announcement was made through a formal notice submitted to the Pakistan Stock Exchange (PSX) on Thursday. According to the company, the export order was initially secured last year and has now been fulfilled successfully, highlighting Liven Pharma’s operational progress and growing international credibility.

This milestone underscores Pakistan’s emerging potential in the global pharmaceutical supply chain, as local companies increasingly seek access to foreign markets. For Liven Pharma, this export marks not only a commercial success but also a validation of its manufacturing standards and compliance with international quality benchmarks.

Last month, the company announced a rights issue worth Rs200 million aimed at bolstering its financial base and funding its expansion initiatives. The company plans to issue 20 million ordinary shares at Rs10 per share, representing approximately 21.5% of its paid-up capital. This allocation translates to 21.496 rights shares for every 100 ordinary shares held at the close of the share transfer books. The move is expected to strengthen liquidity, enhance production capacity, and improve export readiness.

Established on October 21, 1991, and later converted into a public limited company on April 30, 1992, Liven Pharma has built a strong domestic presence in manufacturing pharmaceuticals and allied healthcare products. The company operates under the framework of Pakistan’s evolving corporate governance environment, transitioning from the old Companies Ordinance, 1984, to compliance under the Companies Act, 2017.

Liven Pharma’s successful entry into the Arab market aligns with broader national goals to boost non-traditional exports and expand Pakistan’s pharmaceutical footprint in international markets. Industry analysts see this as a positive signal for investor confidence and a potential catalyst for other local manufacturers to explore regional trade opportunities.

As global demand for cost-effective and reliable medical products rises, Pakistan’s pharmaceutical exporters are increasingly being recognized for their capacity to meet international standards. Liven Pharma’s achievement not only highlights its corporate growth but also reflects the broader resilience and innovation emerging from Pakistan’s industrial sector.

With this export milestone, the company appears poised to accelerate its growth trajectory, aiming to capture new markets, attract investors, and contribute to the diversification of Pakistan’s export portfolio.